Drugs & Aging

, Volume 3, Issue 5, pp 400–407 | Cite as

Calcium Antagonists in the Elderly

  • John G. Kelly
  • Kevin O’Malley
Drug Therapy

Summary

The calcium antagonists are associated with a number of advantages over other antihypertensive agents, such as a lack of metabolic, vascular and respiratory adverse events, yet are effective in reducing blood pressure.

The currently available calcium antagonists are widely used, and new members, particularly of the dihydropyridine group, continue to emerge. These agents may well be considered for use in the management of hypertension and angina in elderly people.

They undergo significant first-pass metabolism and tend to have high values of hepatic clearance with minimal amounts of unchanged drug in the urine. Plasma concentrations tend to be higher in elderly people and for that reason it may be prudent to initiate therapy with lower dosages.

With this caveat, adverse effect profiles seem to be qualitatively and quantitatively similar in younger and older people. At equivalent plasma concentrations, the antihypertensive effect appears similar in young and elderly patients, and clinical studies point to comparable efficacy with other drug classes.

Calcium antagonists do not have adverse renal, respiratory, cardiovascular, metabolic or peripheral vascular effects and therefore may be useful in patients with relevant concomitant disease.

Keywords

Verapamil Nifedipine Diltiazem Calcium Antagonist Amlodipine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abernethy DR, Gutkowska J, Winterbottom LM. Effects of amlodipine, a long acting dihydropyridine calcium antagonist in ageing hypertension. Pharmacodynamics in relation to disposition. Clinical Pharmacology and Therapeutics 48: 76–86, 1990PubMedCrossRefGoogle Scholar
  2. Abernethy DR, Schwartz JB. Pharmacokinetics of calcium antagonists under development. Clinical Pharmacokinetics 15: 1–14, 1988PubMedCrossRefGoogle Scholar
  3. Abernethy DR, Schwartz JB, Todd EL, Luchi R, Snow E. Verapamil pharmacodynamics and disposition in young and elderly hypertensive patients. Annals of Internal Medicine 105: 329–336, 1986PubMedGoogle Scholar
  4. Baksi AK, Edwards JS, Ahr G. A comparison of the pharmacokinetics of nisoldipine in elderly and young subjects. British Journal of Clinical Pharmacology 31: 367–370, 1991PubMedCrossRefGoogle Scholar
  5. Batlouni M, Armaganijan D, Gorayeb N, Magliano MF. Clinical efficacy and tolerability of isradipine in the treatment of mild-to-moderate hypertension in young and elderly patients. Journal of Cardiovascular Pharmacology 19(Suppl. 3): S53–S57, 1992PubMedGoogle Scholar
  6. Blychert E, Edgar B, Elmfeldt D, Hednert A. A population study of the pharmacokinetics of felodipine. British Journal of Clinical Pharmacology 31: 15–24, 1991PubMedCrossRefGoogle Scholar
  7. British Isradipine Hypertension Group. Evaluation of the safety and efficacy of isradipine in elderly patients with essential hypertension. American Journal of Medicine 86: 110–114, 1989Google Scholar
  8. Buhler FR. Age and pathophysiology-oriented antihypertensive response to calcium antagonists. Journal of Cardiovascular Pharmacology 12(Suppl. 8): 5156–5166, 1988Google Scholar
  9. Castleden CM, George CF. The effect of ageing on the hepatic clearance of propranolol. British Journal of Clinical Pharmacology 7: 49–54, 1979PubMedCrossRefGoogle Scholar
  10. Chalmers JP, Smith SA, Wing LM. Hypertension in the elderly: the role of calcium antagonists. Journal of Cardiovascular Pharmacology 12(Suppl. 8): S147–S155, 1988PubMedGoogle Scholar
  11. Cox JP, O’Boyle CA, Mee F, Kelly J, Atkins M, et al. The antihypertensive efficacy of verapamil in the elderly evaluated by ambulatory blood pressure measurement. Journal of Human Hypertension 2: 41–47, 1988PubMedGoogle Scholar
  12. Durnas C, Loi CM, Cusack BJ. Hepatic drug metabolism and aging. Clinical Pharmacokinetics 19: 359–389, 1990PubMedCrossRefGoogle Scholar
  13. Dustan HP. Calcium channel blockers. Potential medical benefits and side effects. Hypertension 13(Suppl 5): 1137–1140, 1989Google Scholar
  14. Echizen H, Eichelbaum M. Clinical pharmacokinetics of verapamil, nifedipine and diltiazem. Clinical Pharmacokinetics 11: 425–449, 1986PubMedCrossRefGoogle Scholar
  15. Eichler H-G, Hiremath A, Katzir D, Blaschke TF, Hoffman BB. Absence of age-related changes in venous responsiveness to nitroglycerin in vivo in humans. Clinical Pharmacology and Therapeutics 42: 521–524, 1987PubMedCrossRefGoogle Scholar
  16. Elliott HL. Calcium antagonists in the treatment of hypertension and angina pectoris in the elderly. Journal of Cardiovascular Pharmacology 13(Suppl. 4): 12–16, 1989CrossRefGoogle Scholar
  17. Elliott HL, Meredith PA, Reid JL, Faulkner JK. A comparison of the disposition of single oral doses of amlodipine in young and elderly subjects. Journal of Cardiovascular Pharmacology 12(Suppl. 7): S64–S66, 1988PubMedCrossRefGoogle Scholar
  18. Faulkner JK, McGibney D, Chasseaud LF, Perry JL, Taylor IW. The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily. British Journal of Clinical Pharmacology 22: 21–25, 1986PubMedCrossRefGoogle Scholar
  19. Fleisch JH, Hooker CS. The relationship between age and relaxation of vascular smooth muscle in the rabbit and rat. Circulation Research 38: 243–250, 1976PubMedCrossRefGoogle Scholar
  20. Forette F, Bellet M, Henry JF, Hervy MP, Poyard-Salmeron C, et al. Effect of nicardipine in elderly hypertensive patients. British Journal of Clinical Pharmacology 20(Suppl. 1): 125S–129S, 1985PubMedCrossRefGoogle Scholar
  21. Garavaglia GE, Lavi CJ, Messerli FH. Systemic haemodynamics. In Amery & Staessen (Eds) Handbook of Hypertension, Vol. 12, Hypertension in the Elderly, pp. 63–69, Elsevier Science Publishers B.V., Amsterdam, 1989Google Scholar
  22. Gilchrist NL, Nicholls MG, Ever TC, Livesey JH, Sainsbury R. A comparison of long acting nifedipine and enalapril in elderly hypertension: a randomized, single blind cross-over study. Journal of Human Hypertension 2: 33–39, 1988PubMedGoogle Scholar
  23. Giles TD, Massie BM. Role of calcium antagonists as initial pharmacologic monotherapy for systemic hypertension in patients over 60 years of age. American Journal of Cardiology 61: 13H–17H, 1988PubMedCrossRefGoogle Scholar
  24. Gribbon B, Pickering TG, Sleight P, Peto R. Effect of age and high blood pressure on baroreflex sensitivity in man. Circulation Research 29: 424–431, 1971CrossRefGoogle Scholar
  25. Hall ST, Harding SM, Evans GL, Pellegatti M, Rizzini P. Clinical pharmacology of lacidipine. Journal of Cardiovascular Pharmacology 17(Suppl. 4): S9–S13, 1991PubMedGoogle Scholar
  26. Hosie J, Mulder AW, Westberg B. Felodipine once daily in elderly hypertensives. Journal of Human Hypertension 5: 49–53, 1991PubMedGoogle Scholar
  27. Kelly JG, O’Malley K. Clinical pharmacokinetics of calcium antagonists. Clinical Pharmacokinetics 23: 1–10, 1992CrossRefGoogle Scholar
  28. Krakoff LR. Nicardipine monotherapy in ambulatory elderly patients with hypertension. American Heart Journal 117: 250–254, 1989PubMedCrossRefGoogle Scholar
  29. Landahl S, Edgar B, Gabrielson M, Lernfelt B, Lundborg P, et al. Pharmacokinetics and blood pressure effects of felodipine in elderly hypertensive patients. A comparison with young healthy subjects. Clinical Pharmacokinetics 14: 374–383, 1988PubMedCrossRefGoogle Scholar
  30. Landmark K, Dale J. Antihypertensive and haemodynamic and metabolic effects of nifedipine slow-release tablets in elderly patients. Acta Medica Scandinavica 218: 389–396, 1985PubMedCrossRefGoogle Scholar
  31. Le Jeunne C, Hughes FC, Munera Y, Ozanne H. Dizziness in the elderly and calcium channel antagonists. Biomedicine and Pharmacotherapy 45: 33–36, 1991CrossRefGoogle Scholar
  32. Lettieri JT, Krol GJ, Yeh SC, Burkholder DE, Zinny M, et al. The effects of age and race on nitrendipine pharmacokinetics and pharmacodynamics. Journal of Cardiovascular Pharmacology 12(Suppl. 4): S129–S132, 1988PubMedCrossRefGoogle Scholar
  33. Lindeman RD. Changes in renal function with aging. Implications for treatment. Drugs & Aging 2: 423–431, 1992CrossRefGoogle Scholar
  34. McGarry K, Laher M, Fitzgerald D, Horgan J, O’Brien E, et al. Baroreflex function in elderly hypertensives. Hypertension 5: 763–766, 1983PubMedCrossRefGoogle Scholar
  35. Meredith PA, Elliott HL, Ahmed JH, Reid JL. Age and the antihypertensive efficacy of verapamil - an integrated pharmacokinetic-pharmacodynamic approach. Journal of Hypertension 5(Suppl. 5): S219–S221, 1987Google Scholar
  36. O’Malley K, Kelly JG. Pharmacokinetics in the elderly. In Amery & Staessen (Eds) Handbook of hypertension, Vol. 12, Hypertension in the elderly, pp. 186–194, Elsevier Science Publishers B.V., Amsterdam, 1989Google Scholar
  37. Opie LH. Calcium channel antagonists: Part VI: Clinical Pharmacokinetics of first and second generation agents. In Opie (Ed.) Clinical use of calcium channel antagonist drugs, pp. 245–279, Kluwer Academic Publishers, Boston, 1989CrossRefGoogle Scholar
  38. Piepho RW, Fendler KJ. Antihypertensive therapy in the aged patient. Clinical Pharmacokinetic considerations. Drugs & Aging 1: 194–211, 1991CrossRefGoogle Scholar
  39. Rizzini P, Castello C, Salvi S, Recchia G. Efficacy and safety of lacidipine, a new long lasting calcium antagonist in elderly hypertensive patients. Journal of Cardiovascular Pharmacology 17(Suppl. 4): S38–S43, 1991PubMedGoogle Scholar
  40. Robertson DRC, Walker DG, Renwick AG, George CF. Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine. British Journal of Clinical Pharmacology 25: 297–305, 1988PubMedCrossRefGoogle Scholar
  41. Scarpace PJ, Turner N, Mader SL. β-Adrenergic function in aging. Basic mechanisms and clinical implications. Drugs & Aging 1: 116–129, 1991CrossRefGoogle Scholar
  42. Schran HF, Jaffe JM, Gonasum LM. Clinical pharmacokinetics of isradipine. American Journal of Medicine 84(Suppl. 3B): 80–89, 1988CrossRefGoogle Scholar
  43. Schwartz JB, Abernethy DR. Responses to intravenous and oral diltiazem in elderly and younger patients with essential hypertension. American Journal of Cardiology 59: 1111–1117, 1987PubMedCrossRefGoogle Scholar
  44. Thulin T. Calcium antagonists - assessment of side effects. Scandinavian Journal of Primary Health Care 1(Suppl.): 81–84, 1990PubMedGoogle Scholar
  45. Tomanek RJ. Coronary vasculature of the aging heart. In Weisfeldt ML (Ed.), The aging heart: its function and response to stress, pp. 115–135, Raven Press, New York, 1980Google Scholar
  46. Vestal RE, Wood AJJ, Shand DG. Reduced beta-adrenoceptor sensitivity in the elderly. Clinical Pharmacology and Therapeutics 26: 181–186, 1979PubMedGoogle Scholar
  47. Wei JY. Use of calcium entry blockers in elderly patients: special considerations. Circulation 80(Suppl. 6): 171–177, 1989Google Scholar
  48. Woodhouse KW, Wynne HA. Age-related changes in hepatic function. Implications for drug therapy. Drugs & Aging 2: 243–255, 1992CrossRefGoogle Scholar
  49. Woodhouse KW, Wynne HA. Age-related changes in liver size and hepatic blood flow. The influence on drug metabolism in the elderly. Clinical Pharmacokinetics 15: 287–294, 1988PubMedCrossRefGoogle Scholar
  50. Yin FCP. The aging vasculature and its effect on the heart. In Weisfeldt ML (Ed.) The aging heart: its function and response to stress, pp. 137–213, Raven Press, New York, 1980Google Scholar
  51. Zing W, Ferguson RK, Vlasses PH. Calcium antagonists in elderly and black hypertensive patients. Therapeutic controversies. Archives of Internal Medicine 151: 2154–2162, 1991PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1993

Authors and Affiliations

  • John G. Kelly
    • 1
  • Kevin O’Malley
    • 2
  1. 1.Research, Elan Corporation plcMonksland, AthloneIreland
  2. 2.Royal College of Surgeons in Ireland, St Stephen’s GreenDublinIreland

Personalised recommendations